Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-Label Study to Evaluate the Long-Term Safety and Efficacy of Tideglusib for the Treatment of Congenital or Childhood Onset DM1 (REACH CDM X)

Next Previous
X
Search
Trial Profile

An Open-Label Study to Evaluate the Long-Term Safety and Efficacy of Tideglusib for the Treatment of Congenital or Childhood Onset DM1 (REACH CDM X)

Status: Recruiting
Phase of Trial: Phase II/III

Latest Information Update: 14 Nov 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tideglusib (Primary)
  • Indications Myotonic dystrophy
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms REACH CDM X
  • Sponsors AMO Pharma

    • Most Recent Events

    • 23 May 2023 Clinician-Completed Congenital DM1 Rating Scale (CDM1-RS) has ben newly added as a primary end-point, thus making "TU" also a trial focus. Timeline for safety end-point is increased from 54 to 86 weeks.
    • 23 May 2023 Planned number of patients changed from 56 to 76.
    • 23 May 2023 Planned End Date changed from 28 Mar 2023 to 28 Mar 2025.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top